| Item type |
デフォルトアイテムタイプ_（フル）(1) |
| 公開日 |
2023-03-18 |
| タイトル |
|
|
タイトル |
The Sensitivity of Human Breast Cancer Stem Cells (ALDH+) Against Doxorubicin Treatment is Associated with PCNA and BIRC5 Gene Expressions |
|
言語 |
en |
| 作成者 |
Dewi, Syarifah
Syahrani, Resda Akhra
Sadikin, Mohamad
Wanandi, Septelia Inawati
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利情報 |
|
|
権利情報 |
Copyright (c) 2018 Hiroshima University Medical Press |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
human breast cancer stem cells |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
cell viability |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
PCNA |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
BIRC5 |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
doxorubicin |
| 主題 |
|
|
主題Scheme |
NDC |
|
主題 |
490 |
| 内容記述 |
|
|
内容記述 |
Introduction: Breast cancer stem cells (BCSCs) are identified as side populations in breast cancer cells owing stem cell properties and tumorigenic characteristics. Previous studies revealed that breast cancer chemotherapy led to BCSC enrichment which contributed to therapy resistance. Our recent in vivo study using Next Generation Sequencing has demonstrated that PCNA - the proliferative gene - and BIRC5 – the anti-apoptosis gene – were under-expressed in human breast tumors after neoadjuvant chemotherapy. This study aimed to verify the role of PCNA and BIRC5 expression in doxorubicin-treated human BCSCs in vitro and its association with cell viability. Method: Human BCSCs (ALDH+) were treated with 0.25 uM of doxorubicin for 2, 4, 6, 8, 10, 12, 14 days respectively. Cell viability was measured using trypan blue exclusion assay and the expressions of PCNA and BIRC4 mRNA were determined using qRT-PCR. Results: This study demonstrated that the viability of ALDH+ BCSCs decreased after 2 days and increased again after 8 days of doxorubicin treatment, indicating the decrease of doxorubicin sensitivity. Interestingly, PCNA and BIRC5 genes were modulated in line with the modulation of cell viability during doxorubicin treatment of human BCSCs. Conclusion: In conclusion, we suggest that the PCNA and BIRC5 expressions play an important role on the BCSCs viability which associated with the sensitivity of doxorubicin treatment. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Hiroshima University Medical Press |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
departmental bulletin paper |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0018-2052 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA00664312 |
| 開始ページ |
|
|
開始ページ |
84 |
| 書誌情報 |
Hiroshima Journal of Medical Sciences
Hiroshima Journal of Medical Sciences
巻 67,
p. 84-90,
発行日 2018-05
|
| 旧ID |
45848 |
HiroshimaJMedSci_67s_84.pdf (275.0 KB)
